Patents Assigned to PROTHIX B.V.
  • Monoclonal antibodies against the active site of factor XI and uses thereof
    Patent number: 11059905
    Abstract: The present invention provides novel anti-factor XI (FXI) antibodies and compositions comprising such antibodies. The anti-FXI antibodies of the invention specifically bind to the active center of FXI and inhibit the functional activity of FXI. The invention further provides humanized versions of the anti-FXI antibodies that are useful in the prevention and treatment of conditions in which pathological thrombus formation or thrombo-embolism are involved. The invention further provides nucleic acid molecules encoding the anti-FXI antibodies, cells expressing the anti-FXI antibodies and methods for producing the anti-FXI antibodies.
    Type: Grant
    Filed: March 23, 2017
    Date of Patent: July 13, 2021
    Assignee: Prothix B.V.
    Inventors: Péter Boross, Cafer Yildiz, Cornelis Erik Hack
  • Monoclonal antibodies against the active site of factor XI and uses thereof
    Publication number: 20190106509
    Abstract: The present invention provides novel anti-factor XI (FXI) antibodies and compositions comprising such antibodies. The anti-FXI antibodies of the invention specifically bind to the active center of FXI and inhibit the functional activity of FXI. The invention further provides humanized versions of the anti-FXI antibodies that are useful in the prevention and treatment of conditions in which pathological thrombus formation or thrombo-embolism are involved. The invention further provides nucleic acid molecules encoding the anti-FXI antibodies, cells expressing the anti-FXI antibodies and methods for producing the anti-FXI antibodies.
    Type: Application
    Filed: March 23, 2017
    Publication date: April 11, 2019
    Applicant: Prothix B.V.
    Inventors: Péter Boross, Cafer Yildiz, Cornelis Erik Hack
  • USE OF ANTI-FACTOR XI ANTIBODIES FOR PREVENTION OF THROMBUS FORMATION
    Publication number: 20180118850
    Abstract: The present invention relates to binding molecules such as antibodies that specifically bind plasma coagulation factor XI and that inhibit factor XI activation and/or activity. The factor XI-binding molecules of the invention maybe sued in methods for preventing or treating diseases, disorders and/or condition that are mediated by factor XI activation and/or wherein inhibition of factor XI has a beneficial effect.
    Type: Application
    Filed: December 18, 2017
    Publication date: May 3, 2018
    Applicant: Prothix B.V.
    Inventor: Erik HACK
  • USE OF ANTI-FACTOR XI ANTIBODIES FOR PREVENTION OF THROMBUS FORMATION
    Publication number: 20140194600
    Abstract: The present invention relates to binding molecules such as antibodies that specifically bind plasma coagulation factor XI and that inhibit factor XI activation and/or activity. The factor XI-binding molecules of the invention may used in methods for preventing or treating diseases, disorders and/or conditions that are mediated by factor XI activation and/or wherein inhibition of factor XI has a beneficial effect.
    Type: Application
    Filed: September 24, 2013
    Publication date: July 10, 2014
    Applicant: Prothix B.V.
    Inventor: Erik HACK
  • USE OF ANTI-FACTOR XI ANTIBODIES FOR PREVENTION OF THROMBUS FORMATION
    Publication number: 20120259097
    Abstract: The present invention relates to binding molecules such as antibodies that specifically bind plasma coagulation factor XI and that inhibit factor XI activation and/or activity. The factor XI-binding molecules of the invention may used in methods for preventing or treating diseases, disorders and/or conditions that are mediated by factor XI activation and/or wherein inhibition of factor XI has a beneficial effect.
    Type: Application
    Filed: June 19, 2012
    Publication date: October 11, 2012
    Applicant: PROTHIX B.V.
    Inventor: Erik HACK